Skip to main content
2025 STS Annual Meeting Main banner
Back

General Thoracic

Multimodal Treatment of Pleural Mesothelioma after the MARS-2 trial: Will We Change Our Ways?

Adjuvant Systemic and Immunotherapy Options in the Treatment of Pleural Mesothelioma

Saturday, January 25, 2025
11:18am – 11:26am PT
Location: 408A

    Invited Speaker(s)

  • Jennifer Marie Suga, MD MPH (she/her/hers)

    Medical Director, Adult Kaiser Permanente Oncology Clinical Trials
    The Permanente Medical Group
    Vallejo, California, United States

    Disclosure(s): Astrazeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Strata Oncology: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Disclosure(s):
Jennifer Marie Suga, MD MPH: Astrazeneca: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Strata Oncology: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)